Long-Term Effects of LSD: A Clinician’s Guide to HPPD, Psychological Risks, Brain Changes, and What Decades of Acid Use Can Leave Behind

What the evidence shows about the lasting effects of LSD use on the brain and on mental health, the recognised diagnosis of hallucinogen persisting perception disorder, the risk of precipitating psychotic illness in vulnerable individuals, the relationship between LSD use and substance use disorders, and what treatment looks like when long-term use has produced clinical problems.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

LSD does not produce the physical organ damage or chronic medical illness that long-term alcohol, opioid, or stimulant use produce, but it does carry several documented long-term effects that matter clinically. The most well-characterised is hallucinogen persisting perception disorder, a DSM-5 diagnosis in which perceptual disturbances including visual snow, palinopsia (trailing of moving objects), false motion perception, and lasting changes in colour and depth perception persist for weeks, months, or years after the last use. A second long-term risk is precipitation or worsening of serious mental illness, particularly in adolescents and young adults with personal or family history of schizophrenia, bipolar disorder, or major depression. Persistent psychological changes, including durable shifts in worldview, religious or spiritual belief, and personality traits, are reported by many long-term users and may be welcome or unwelcome depending on the individual. Brain imaging studies show modest functional changes after repeated LSD use, and some users develop a flashback phenomenon distinct from HPPD. Tolerance develops rapidly so daily use is uncommon, but psychological dependence and patterns of use that interfere with daily life can develop. The substance does not produce the cardiovascular damage or addiction profile of harder drugs, but the long-term effects on mental health and perception are real and warrant clinical attention.

What LSD is and what we know about its long-term effects

Lysergic acid diethylamide, abbreviated as LSD, is a synthetic hallucinogenic compound first synthesised by Albert Hofmann at Sandoz Laboratories in 1938 and discovered to be psychoactive in 1943. The substance is one of the most potent psychoactive compounds known, active at doses measured in micrograms rather than milligrams. The classic recreational dose ranges from 50 to 200 micrograms, with current research and microdosing protocols using smaller amounts. LSD acts primarily as a partial agonist at the serotonin 5-HT2A receptor, with additional effects on other serotonin receptors and on dopamine systems. The medication is classified as a Schedule I controlled substance in the United States and most other jurisdictions, reflecting the federal assessment of high abuse potential and no accepted medical use, though clinical research has been resumed in the past decade examining LSD and related psychedelics for potential applications in psychiatry.

The pattern of LSD use in the modern era differs substantially from the 1960s pattern. Most current users use the substance occasionally rather than frequently, often in social or festival settings, and many describe a deliberate spiritual or growth framing for the experience. A substantial minority of users have moved toward microdosing, taking sub-perceptual amounts of LSD several times per week with the goal of improving mood, creativity, or cognitive function. The evidence base for microdosing is limited and the long-term effects of this newer use pattern are not well-characterised. Recreational use in social settings remains common, particularly among college-age young adults at festivals, in dance scenes, and in psychedelic-friendly subcultures.

Long-term effects of LSD use need to be understood against this changing pattern. The classic literature on LSD harm comes largely from cases of heavy use in the 1960s and 1970s, when the substance was new, doses were less standardised, and the cultural context was different. The current evidence base reflects newer studies of less intensive use patterns, often with users who frame their use in spiritual or therapeutic terms. The conclusions overlap but do not perfectly align, and clinicians assessing long-term effects in current patients need to consider both bodies of evidence.

Hallucinogen persisting perception disorder (HPPD)

Hallucinogen persisting perception disorder is the most well-characterised long-term effect of LSD use and is the only one with a specific DSM-5 diagnostic code (292.89). The diagnosis requires the re-experiencing of perceptual symptoms that were experienced during prior hallucinogen intoxication, causing clinically significant distress or impairment, and not better explained by another medical or psychiatric condition. The perceptual symptoms include visual snow, palinopsia (positive afterimages of moving objects, sometimes called trailing), illusory motion of stationary objects, false perception of motion in the peripheral vision, halos around objects, and a variety of distortions of size, depth, and colour.

HPPD is distinct from flashbacks. A flashback is a discrete episode in which the person briefly re-experiences elements of a prior LSD trip, including emotional and perceptual content, lasting seconds to minutes. HPPD is a more sustained perceptual disturbance that is present continuously or near-continuously and that does not have the same dream-like quality as a flashback. Both phenomena are reported by LSD users; HPPD is the more clinically significant diagnosis because of its sustained nature and its impact on daily functioning.

The prevalence of HPPD in LSD users is not precisely known. Estimates from clinical samples and surveys range from 4 to 15 percent of repeated users developing some form of persistent perceptual disturbance, with a smaller percentage developing the severe and impairing form that meets full DSM-5 criteria. Risk factors include frequent use, high doses, polysubstance use particularly involving cannabis and stimulants, anxiety disorders, and possibly genetic factors that affect serotonergic neurotransmission. The condition can persist for months to years and in some cases is permanent.

Treatment of HPPD is challenging because no medication has consistent evidence of effectiveness. Case reports and small studies suggest possible benefit from clonidine, certain antiepileptic medications including lamotrigine, and SSRIs. Benzodiazepines may temporarily reduce the perceptual disturbance but are generally avoided because of dependence risk. The most important step in management is complete cessation of LSD and related hallucinogens, avoidance of triggers such as cannabis and stress, and supportive treatment of the anxiety and depression that often accompany the perceptual disturbance. Many patients with HPPD adapt over time, with the perceptual symptoms either improving or becoming less distressing through familiarity.

Mental health risks: psychosis, bipolar disorder, and depression

The relationship between LSD use and serious mental illness is one of the more clinically important long-term effects and one of the more contested. The classic concern, dating from the 1960s, was that LSD use could precipitate schizophrenia or other psychotic illness in vulnerable individuals. Subsequent research has clarified the picture: LSD does not cause schizophrenia in people who would not otherwise develop it, but it can precipitate the onset of a psychotic illness in someone who is vulnerable, accelerating an illness that might otherwise have developed years later or might have remained subclinical.

The vulnerable population includes anyone with personal history of psychotic symptoms, family history of schizophrenia or other primary psychotic illness, family history of bipolar disorder, and personal history of severe major depression with psychotic features. The risk of LSD precipitating illness in these populations is substantially higher than in people without these risk factors. The clinical implication is that LSD use is strongly discouraged in adolescents and young adults with any of these vulnerabilities, and that careful psychiatric screening is appropriate before participation in any psychedelic-assisted therapy research.

Bipolar disorder is a particular concern because LSD can precipitate manic episodes in vulnerable individuals, and a manic episode triggered in this way can be the index event that establishes the bipolar diagnosis. Subsequent episodes may then occur spontaneously, with the LSD use having moved the clinical course onto a more difficult trajectory. The same pattern is described with cannabis use and with stimulant use, both of which can precipitate manic episodes in vulnerable individuals.

Major depressive disorder can also be precipitated or worsened by LSD use, particularly when the user experiences difficult or destabilising trips that they cannot integrate effectively. The post-trip period, particularly for naive users, can include several days of low mood, fatigue, and emotional rawness that is sometimes called the comedown. Most people resolve this within a few days, but some develop a more sustained depressive episode that meets clinical criteria and requires treatment. People with pre-existing depression who use LSD may experience worsening of their depression after the experience rather than the improvement that they may have anticipated.

Psychological changes and worldview shifts

Many people who have used LSD describe lasting psychological changes that they attribute to the experiences. These changes can include shifts in religious or spiritual belief, alterations in the perceived meaning of life, changes in personality traits including increased openness to experience, and durable shifts in attitudes toward nature, mortality, and human relationships. The reports come both from users who frame their use as recreational and from those who used the substance in research, therapeutic, or ceremonial contexts. The changes have been documented in modern clinical research using validated personality and outcome measures.

Whether these changes are good or bad depends on the individual and on the context. Many users describe the changes as positive and life-affirming, including increased connection with others, reduced fear of death, and a clearer sense of personal values. Other users find the changes disorienting, particularly when they conflict with the user’s prior beliefs, religious commitments, professional identity, or relationships. The challenge of integrating significant worldview shifts can produce its own clinical problems, including identity confusion, social isolation, and crisis of vocation or relationship.

Research from Johns Hopkins, Imperial College London, and other groups has documented durable increases in the personality trait of openness to experience following high-dose psilocybin in clinical research, with similar findings beginning to emerge for LSD. Openness includes intellectual curiosity, aesthetic sensitivity, interest in novel experiences, and willingness to consider unconventional ideas. The change is generally small in magnitude but is sustained for at least a year and possibly longer, and represents one of the few documented examples of a psychiatric medication producing a measurable change in adult personality.

These psychological changes are not pathological in the strict sense and do not constitute a long-term harm in the way that HPPD or precipitated psychotic illness do. They do, however, mean that LSD use is a more meaningful undertaking than recreational use of substances like alcohol or cannabis, and that users may benefit from preparation and integration support that helps them make sense of any significant changes that emerge.

Brain changes documented in imaging studies

Modern brain imaging has produced a more detailed picture of how LSD acts on the brain than was previously available. The acute effects of LSD include reduced activity in the default mode network, a set of brain regions that are active during self-referential thinking and that have been implicated in depression, anxiety, and rumination. The reduction in default mode network activity during the LSD experience may underlie the dissolution of ordinary self-experience that users describe, and may be related to the therapeutic effects that have been observed in clinical trials of psilocybin and LSD for treatment-resistant depression.

Imaging studies of long-term users are limited, but available data suggest some persistent changes in connectivity between brain regions, particularly involving the default mode network and the salience network. The functional significance of these changes is not fully understood, and the changes do not constitute brain damage in the classical sense of cell death or structural injury. They represent altered patterns of brain activity that may underlie some of the lasting psychological changes reported by users.

Structural brain damage from LSD use is not a documented phenomenon. The substance is not neurotoxic at typical recreational doses, does not produce the structural changes seen with chronic alcohol use, methamphetamine use, or repeated head injury, and has not been associated with dementia or other neurodegenerative conditions. The myth that LSD produces holes in the brain, common in 1960s anti-drug education, has no basis in evidence.

Tolerance, dependence, and the addiction potential

LSD is unusual among psychoactive substances in producing rapid and substantial tolerance, with the tolerance developing within days of repeated use. A user who takes 100 micrograms on Monday may need 200 to 400 micrograms on Tuesday to produce a similar effect, and the dose required continues to escalate with each successive day of use. Cross-tolerance with other 5-HT2A agonists including psilocybin and mescaline also develops, so daily use of any of these substances rapidly diminishes their effect. The tolerance generally resolves within five to seven days of abstinence.

This rapid tolerance pattern is one reason that LSD does not produce the daily compulsive use pattern characteristic of opioids, stimulants, alcohol, or benzodiazepines. The substance simply does not work day after day, so daily use is uncommon and is not typically rewarding. The classic addiction pattern that develops with stimulants, opioids, and alcohol does not develop with LSD because the pharmacology does not support it.

Psychological dependence on LSD is possible and is reported in some users. The pattern involves frequent use over weeks or months despite recognised harms, difficulty stopping despite intention to do so, and continued use despite adverse consequences. The DSM-5 includes hallucinogen use disorder as a diagnostic category covering this pattern. The diagnosis is uncommon compared with use disorders of other substances, but it does exist and warrants clinical attention when it does.

Concurrent substance use is the more common clinical concern in this population. LSD users frequently use cannabis, MDMA, ketamine, and other substances, and patterns of polysubstance use often involve LSD as one component among many. Treatment in this population requires attention to the whole pattern rather than to LSD alone, and the substances that are more addictive (alcohol, stimulants, opioids) typically need to be addressed first.

Cardiovascular and physical health considerations

LSD produces acute cardiovascular effects including modest increases in blood pressure, heart rate, and body temperature. These effects are mediated by the substance’s action on 5-HT2A receptors in the cardiovascular system and by the autonomic nervous system response to the altered state. In healthy young adults the cardiovascular effects are typically well-tolerated, but they can produce problems in people with pre-existing cardiovascular disease, uncontrolled hypertension, or recent cardiac events. The substance is generally contraindicated in these populations.

Long-term cardiovascular effects of LSD use are not well-characterised. The substance does not produce the chronic cardiovascular damage seen with stimulants, alcohol, or tobacco. Case reports of valvular heart disease have appeared with very high-dose long-term use, related to chronic 5-HT2B receptor stimulation, but the syndrome is rare and is mainly a concern with the much higher exposure produced by some daily microdosing patterns that have been studied in clinical research rather than recreational use.

Acute physical risks during the LSD experience include falls, accidents, and unintentional injuries from impaired judgement, drowning, and traffic accidents if the person attempts to drive. These risks are particularly elevated when LSD is combined with alcohol or other substances. Death directly attributable to LSD use is rare; the substance has a very high therapeutic index, with the recreational dose far below the LD50 in animal studies, but accidents during the intoxication and pre-existing medical conditions can produce fatalities indirectly.

LSD versus other hallucinogens

LSD shares many long-term effects with other classical hallucinogens including psilocybin (the active ingredient in psilocybin mushrooms), mescaline (in peyote and San Pedro cactus), and DMT (in ayahuasca and crystalline form). All of these substances act primarily on the 5-HT2A receptor, all produce similar acute psychological effects, and all carry similar risks of HPPD, precipitation of psychotic illness in vulnerable individuals, and lasting psychological changes. The differences between them are mainly in duration of effect, dose-response curve, and cultural context of use.

Some hallucinogens act on different receptors and have different long-term profiles. Ketamine acts at NMDA receptors and produces distinct long-term effects including bladder damage and cognitive impairment with frequent use, neither of which are seen with LSD. MDMA acts on serotonin and dopamine release and is associated with longer-term mood and cognitive effects that are not characteristic of LSD. The 2C-x series of substituted phenethylamines act similarly to LSD but have less established safety data and higher variability in subjective effects. NBOMe compounds, which are sometimes sold as LSD on blotter paper, have substantially worse safety profiles than LSD itself and have been implicated in several recent deaths.

When LSD use coexists with alcohol use disorder

Alcohol use disorder, which is the clinical term for what most people call alcoholism, frequently coexists with LSD use, particularly in the festival and dance music subcultures where both substances are common. The pattern of heavy weekend drinking combined with occasional LSD use can develop into a problematic alcohol pattern that the user does not see as an alcohol problem because they associate their substance use with the psychedelic rather than the drinking. The alcohol use produces the daily-life damage, the LSD produces the destabilising experiences, and both contribute to the clinical picture.

Treatment of alcohol use disorder co-occurring with LSD use focuses primarily on the alcohol because that is the substance producing the daily harm. Outpatient counselling, medication-assisted treatment with naltrexone or acamprosate, intensive outpatient programs, and residential rehab are all options depending on severity. Once the alcohol use is addressed, decisions about continued LSD use can be made more clearly. Phuket Island Rehab provides residential addiction medicine treatment for international patients with alcohol use disorder, hallucinogen use, and the underlying mental health concerns that often drive both.

Treatment when long-term LSD use has produced clinical problems

Patients presenting with HPPD, precipitated psychotic or bipolar illness, or hallucinogen use disorder following long-term LSD use need integrated psychiatric and addiction medicine care. The first step is complete cessation of LSD and related hallucinogens, often supported by addiction counselling and peer support. Avoidance of triggers including cannabis, stress, and alcohol is important because these substances can worsen HPPD symptoms and can destabilise mental health recovery.

Treatment of any precipitated psychotic illness follows standard psychiatric protocols, with antipsychotic medication, monitoring, and structured outpatient or inpatient care as needed. The course of LSD-precipitated psychotic illness varies; some patients have a single episode that resolves with treatment and does not recur, while others have a chronic course that resembles primary schizophrenia. Bipolar disorder triggered by LSD use is treated with mood stabilisers and standard bipolar care. Depression following difficult LSD experiences responds to standard antidepressant treatment combined with integration support that helps the patient make sense of what happened.

Integration is a concept that has emerged from the psychedelic-assisted therapy field and refers to the process of making sense of and incorporating insights from a psychedelic experience into ordinary life. For patients with difficult or unresolved LSD experiences, structured integration support, either with a therapist trained in this area or with a peer-led integration group, can help convert the experience from a source of ongoing distress into a meaningful life event. Many ordinary psychotherapists are now trained in psychedelic integration, and the field is developing rapidly.

Summary

LSD does not produce the physical organ damage that long-term alcohol, opioid, or stimulant use produce, but it carries several documented long-term effects that matter clinically. Hallucinogen persisting perception disorder is the most well-characterised, with perceptual disturbances persisting for weeks, months, or years after use. Precipitation or worsening of serious mental illness in vulnerable individuals is the most clinically important risk. Persistent psychological changes including durable shifts in personality, worldview, and belief are documented and may be welcome or unwelcome depending on the individual. Brain imaging shows functional changes but not structural damage. The substance does not produce the addiction profile of harder drugs, but psychological dependence and concurrent substance use are real concerns. Treatment is available when long-term use has produced clinical problems, and integrated care that addresses any HPPD, psychiatric illness, and concurrent substance use produces the best outcomes. As Dr. Ponlawat Pitsuwan summarises, “LSD is one of the more interesting substances in clinical addiction medicine because the long-term effects look quite different from the long-term effects of more conventionally addictive drugs. The mental health risks are real and need to be taken seriously, particularly in vulnerable young people, but the medical risks are modest and the addiction profile is unusual.”

Frequently asked questions

What are the long-term effects of LSD use?

Long-term effects include hallucinogen persisting perception disorder with sustained visual disturbances, precipitation or worsening of serious mental illness in vulnerable individuals, durable psychological changes including shifts in personality and worldview, functional brain changes documented in imaging studies, and psychological dependence in a subset of users. The substance does not produce the physical organ damage seen with alcohol, opioids, or stimulants.

What is HPPD?

Hallucinogen persisting perception disorder is a DSM-5 diagnosis in which perceptual disturbances persist after hallucinogen use. Symptoms include visual snow, palinopsia (trailing of moving objects), illusory motion, halos around objects, and distortions of size or depth. The condition can persist for weeks, months, or years. Treatment includes complete cessation of hallucinogens, avoidance of triggers, and supportive treatment of accompanying anxiety and depression.

Can LSD cause permanent brain damage?

LSD does not produce structural brain damage in the classical sense of cell death or structural injury. Functional changes in brain connectivity have been documented in long-term users but do not constitute brain damage. The myth that LSD produces holes in the brain has no scientific basis. The substance is not neurotoxic at typical recreational doses.

Can LSD trigger schizophrenia?

LSD can precipitate the onset of schizophrenia or related psychotic illness in vulnerable individuals, accelerating an illness that might otherwise have developed years later or might have remained subclinical. LSD does not cause schizophrenia in people who would not otherwise develop it. Anyone with personal or family history of psychotic illness should not use LSD.

Is LSD addictive?

LSD does not produce the classic addiction pattern of opioids, stimulants, alcohol, or benzodiazepines. Tolerance develops rapidly so daily use is not rewarding, and the substance does not produce the dopamine reward circuit changes that underlie most addictions. Psychological dependence is possible and hallucinogen use disorder is a DSM-5 diagnosis, but the prevalence is low compared with other substance use disorders.

Can LSD cause flashbacks years later?

Yes, flashbacks (brief re-experiencing of trip content) have been reported in some users months or years after the last use. These are distinct from HPPD, which involves sustained perceptual disturbance. Flashbacks may be triggered by stress, sleep deprivation, or use of other substances. The frequency tends to decrease with time since last use.

Sources

• U.S. Drug Enforcement Administration (DEA). LSD drug fact sheet. https://www.dea.gov/factsheets/lysergic-acid-diethylamide
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
• Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence. 2003;69(2):109-119. https://www.sciencedirect.com/science/article/abs/pii/S0376871602002975
• Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42:2105-2113. https://www.nature.com/articles/npp201784
• MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology. 2011;25(11):1453-1461. https://journals.sagepub.com/doi/10.1177/0269881111420188
• National Institute on Drug Abuse (NIDA). Hallucinogens. https://nida.nih.gov/research-topics/hallucinogens
• Substance Abuse and Mental Health Services Administration (SAMHSA). National Helpline. https://www.samhsa.gov/find-help/national-helpline

LSD, lysergic acid diethylamide, acid, hallucinogen, psychedelic, 5-HT2A receptor, serotonin, partial agonist, Albert Hofmann, Sandoz, microdosing, Schedule I controlled substance, DEA, FDA, hallucinogen persisting perception disorder, HPPD, visual snow, palinopsia, trailing, illusory motion, halos, flashbacks, DSM-5, hallucinogen use disorder, default mode network, salience network, brain imaging, fMRI, neurotoxicity, schizophrenia, primary psychotic illness, bipolar disorder, major depressive disorder, manic episode, depressive episode, psilocybin, mescaline, DMT, ketamine, MDMA, 2C-x series, NBOMe, openness to experience, personality change, Johns Hopkins, Imperial College London, Robin Carhart-Harris, integration, psychedelic-assisted therapy, alcohol use disorder, polysubstance use, cannabis, clonidine, lamotrigine, SSRIs, antipsychotics, mood stabilisers, 5-HT2B receptor, valvular heart disease, cardiovascular effects, LD50, therapeutic index, NIDA, SAMHSA, NHS, residential rehab, Phuket Island Rehab, addiction medicine, dual diagnosis.